Compare Eli Lilly And Co (LLY) vs TKO Group Holdings Inc (TKO) Price & Performance

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.

LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.

TKO trades at $178.01, down 0.35% on the day, near its 52-week low of $174.58 (Defense World, 2026-10-02). The stock is technically bearish with mixed earnings history, including a Q2 2026 EPS miss. Revenue grew to $5.3B in 2026 with a net profit margin of 4.32%. A quarterly dividend of $0.79 is scheduled for payment on September 30, 2026.

Wall Street maintains a strong buy consensus (89% buy ratings) with a $227 price target, suggesting significant upside. Key risks include earnings volatility and competitive pressures in sports entertainment. Positive catalysts are media rights deals and live event momentum, but the stock faces near-term technical headwinds.